LNCaP
Marca : CLS Cell Lines Service
LNCaP Cells
Key points about the LNCaP cell line
Description | LNCaP cells, derived from a metastatic lesion in a lymph node of a prostate cancer patient, represent a critical tool in prostate cancer research, particularly for studying the role of androgens and androgen receptor (AR) dynamics in cancer progression. The LNCaP cell line is characterized by their androgen-sensitive growth and offers a window into the mechanisms underlying prostate cancer's response to hormonal manipulation. As a model for metastatic prostate cancer, parental LNCaP cells and their sublines, such as the LNCaP clone FGC, provide clinically relevant insights into disease progression, especially in the context of metastasis to bone, forming osteoblastic lesions akin to those observed in human prostate cancer. The LNCaP human prostate cancer cell line expresses a mutated form of the AR gene with broader steroid-binding specificity and therefore is pivotal for understanding the complex interplay between AR activity and prostate cancer progression. This includes the examination of AR downstream targets like PSA and NKx3.1, which are crucial for prostatic epithelial cell function. LNCaP cells are further used in cytotoxicity studies such as those induced by ripl or the potential therapeutic effects of compounds like amygdalin, within the scope of intracellular drug delivery strategies. In summary, the human prostate carcinoma cell line LNCaP serves as a cornerstone in understanding the role of androgens in cancer progression and prostate cancer, offering insights into hormone-responsive cancers, the challenges of resistant prostate cancer, and the potential for therapeutic interventions. The LNCaP cell line is considered one of the classic and most widely used human prostate cancer cell lines, alongside DU145 and PC3 cells. |
---|---|
Organism | Human |
Tissue | Prostate |
Disease | Carcinoma |
Metastatic site | Left supraclavicular lymph node |
Synonyms | LNCAP, LNCap, Ln-Cap, Lymph Node Carcinoma of the prostate |
Properties of the prostate cancer cell line LNCaP
Age | 50 years |
---|---|
Gender | Male |
Ethnicity | Caucasian |
Morphology | Epithelial-like |
Growth properties | Adherent, clusters |
Documentation
Citation | LNCaP (Cytion catalog number 300265) |
---|---|
Biosafety level | 1 |
Genotype
Receptors expressed | Androgen, estrogen |
---|---|
Protein expression | p53 positive |
Tumorigenic | Yes, in nude mice |
Products | human prostatic acid phosphatase, prostate specific antigen |
Karyotype | pseudodiploid male, seven marker chromosomes, modal number = 46, range = 33 to 91 |
Handling the androgen-sensitive LNCaP cell line
Culture Medium | EMEM, w: 2 mM L-Glutamine, w: 1.5 g/L NaHCO3, w: EBSS, w: 1 mM Sodium pyruvate, w: NEAA (Cytion article number 820100c) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Passaging solution | Accutase |
Doubling time | 60 hours |
Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
Split ratio | A ratio of 1:3 to 1:6 is recommended |
Seeding density | 1 to 2 x 10^4 cells/cm^2 |
Fluid renewal | Every 3 days |
Freezing recovery | After thawing, plate the cells at 5 x 10^4 cells/cm^2 and allow the cells to recover from the freezing process and to adhere for at least 24 hours. |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Quality control
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile | Amelogenin: x,y CSF1PO: 10,11 D13S317: 10,12 D16S539: 11 D5S818: 11,12 D7S820: 9.1,10.3 TH01: 9 TPOX: 8,9 vWA: 16,18 D3S1358: 16 D21S11: 29,31.2 D18S51: 11,12 Penta E: 12,16 Penta D: 12,12.4 D8S1179: 12,14 FGA: 19,20 |
HLA alleles | A*: 01:01:01, 02:01:01 B*: 08:01:01, 37:01:01 C*: 06:02:01, 07:01:01 DRB1*: 03:01:01, 10:01:01 DQA1*: 01:05:01, 05:01:01 DQB1*: 02:01:01, 05:01:01 DPB1*: 02:01:02G, 04:02:01G E: 01:01:01 |